Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | GLI1 | P08151 | 1/20 | 0.37 |
| ▸ | GLI2 | P10070 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3408819 | 0.93 | OPRM1 (0.46) | OPRM1OPRL1MAPK14TACR1GLI1 | |
| SCHEMBL3404179 | 0.80 | EPHX1 (0.46) | OPRM1OPRL1EPHX1CYP2D6EPHX2 | |
| SCHEMBL3409366 | 0.80 | OPRM1 (0.48) | OPRM1OPRL1TACR1 | |
| SCHEMBL3405988 | 0.77 | OPRM1 (0.48) | OPRM1OPRL1TACR1 | |
| SCHEMBL3409871 | 0.76 | OPRL1 (0.59) | OPRM1OPRL1 | |
| SCHEMBL3409353 | 0.76 | HDAC1 (0.46) | OPRM1OPRL1MAPK14 | |
| SCHEMBL3408818 | 0.76 | OPRM1 (0.44) | OPRM1OPRL1EPHX1CYP2D6EPHX2 | |
| SCHEMBL13733764 | 0.73 | OPRM1 (0.62) | OPRM1OPRL1 | |
| SCHEMBL3405037 | 0.73 | OPRM1 (0.52) | OPRM1OPRL1 | |
| SCHEMBL3410140 | 0.72 | EPHX1 (0.42) | OPRM1OPRL1EPHX1CYP2D6EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254883-B1 | SUBSTITUTED INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-11-26 | — | — | EP | claimed |
| US-20130116283-A1 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2013-05-09 | — | — | US | claimed |
| EP-2254883-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-01 | — | — | EP | claimed |
| WO-2009103552-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-08-27 | — | — | WO | claimed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| US-9206156-B2 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| EP-2254883-B1 | SUBSTITUTED INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20130116283-A1 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2013-05-09 | — | — | US | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215828-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | OPRM1 30/4885OPRL1 25/4885EPHX1 2955/4885 |
| US-20130116283-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | OPRM1 30/4885OPRL1 25/4885EPHX1 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.